<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Daiichi Sankyo Co., Ltd.

    Daiichi Sankyo Co., Ltd.

    Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...

    Founded on September 28, 2005 through the merge...

    Filing Type:    PU
    Incyte Corporation

    Incyte Corporation

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...

    Incyte Corporation is a Wilmington, Delaware-ba...

    Filing Type:    PU
    Natural Health Trends Corp.

    Natural Health Trends Corp.

    Natural Health Trends Corporation (NASDAQ: NHTC) is an international direct-sellin...

    Natural Health Trends Corporation (NASDAQ: NHTC...

    Filing Type:    PU
    Bioanalytical Systems, Inc.

    Bioanalytical Systems, Inc.

    BASi provides drug discovery and development services and analytical instruments t...

    BASi provides drug discovery and development se...

    Filing Type:    PU
    Admedus Ltd.

    Admedus Ltd.

    Admedus Limited is a bio medical group. The Group commercializes tissue engineerin...

    Admedus Limited is a bio medical group. The Gro...

    Filing Type:    PR
    Exact Sciences Corporation

    Exact Sciences Corporation

    Exact Sciences Corp. (NASDAQ: EXAS) is committed to playing a role in the eradicat...

    Exact Sciences Corp. (NASDAQ: EXAS) is committe...

    Filing Type:    PU
    PDS Biotechnology Corporation

    PDS Biotechnology Corporation

    PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...

    PDS Biotechnology has a growing pipeline of cli...

    Filing Type:    PU
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Sorrento Therapeutics, Inc.

    Sorrento Therapeutics, Inc.

    Sorrento’s lead programs with short-term milestones consist of two clinical stag...

    Sorrento’s lead programs with short-term mile...

    Filing Type:    PU
    Puma Biotechnology Inc

    Puma Biotechnology Inc

    Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the develo...

    Puma Biotechnology, Inc. is a biopharmaceutical...

    Filing Type:    PU
    Fate Therapeutics, Inc.

    Fate Therapeutics, Inc.

    We are a biopharmaceutical company dedicated to the development of programmed cell...

    We are a biopharmaceutical company dedicated to...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.